Presentation - What to control? CQAs and CPPs
FDA MaPP “Applying ICH Q8, Q9, Q10 ... commensurate with their risk to the process and process output. In other words, a higher degree of control is appropriate for attributes or parameters that pose a higher risk. – Perception of criticality …
Download Presentation - What to control? CQAs and CPPs
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
GUIDANCE ON ASPECTS OF CLEANING VALIDATION IN …
apic.cefic.orgIn addition, APIC has aligned this guidance with the ISPE Risk MaPP Guide1 that follows the Quality Risk Management Processes as described in the ICH Q9 Guidance on Quality Risk Management. A further revision of the Guidance has now been done to include the general principles of the
Cleaning Validation : Defining Limits and Doing MACO ...
ispenordic.nemtilmeld.dk(Baseline Guide ISPE Risk-MaPP) : « …..A substance-specific dose that is unlikely to cause an adverse effect if an individual is exposed at or below this dose every day for a lifetime. » • Unit : µg/Day • Standard body Weight : EMA 50kg, FDA 60kg 2nd: new GMP approach…
Safety Guidelines and Good Industry Practices For Oil ...
unece.orgHIRA Hazard identification and risk assessment IEC International Electrotechnical Commission ITPM Inspection, testing and preventive maintenance MAPP Major-accident prevention policy OTMS Oil terminal management system RP Recommended Practice (of the API) Vlll
Understanding COMAH Competent Authority for the Control …
www.hse.gov.ukPrepare a major accident prevention policy (MAPP) 10 All measures necessary 12 Duties relevant to top-tier COMAH sites only Prepare a COMAH safety report 13 Prepare and test an on-site emergency plan 16 ... the risk to the community. Although a separate regulatory process from COMAH, we recommend that you
Datenschutzhinweis der Telekom Deutschland GmbH …
www.telekom.deMapp (vorm. Erläuterungen und Definitionen Webtrekk) Wir möchten, dass sie unsere Webseiten gerne nutzen und unsere Produkte und Dienste in Anspruch nehme n. Daran haben wir ein wirtschaftliches ... Risk.Ident Betrugsprävention Code-Snippet Deutschland Deutschland
CLEANING VALIDATION WITH RISK ASSESSMENT
www.usp-pqm.orgthe Risk-MaPP Guide A. Walsh. 2 . Points Out That From Risk - MaPP Definition, The ADE is a . Very Conservative Value. Thus Possibly Artificially Reducing The Cleaning Limit Based on ADE as Defined in the Risk-MaPP. The Risk-MaPP Was Developed For “Compounds Of Concern”, These “Classes” of Compounds Were to Include Hormones, Cytotoxic